Biomerica, Inc. (BMRA) vs Sonoma Pharmaceuticals, Inc. (SNOA)

A side-by-side comparison of Biomerica, Inc. and Sonoma Pharmaceuticals, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — BMRA vs SNOA

growth of $100 · dividends reinvested · last 10y
BMRA -90.6% (-21.1%/yr)SNOA -99.8% (-47.6%/yr)BMRA compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $10020182020202220242026$9$0
BMRA SNOA

BMRA vs SNOA: by the numbers

  • •BMRA is the larger company ($7M vs $6M market cap).
  • •Both run net losses; SNOA's is the smaller (-10.33% vs -84.79% net margin).
  • •SNOA grew revenue faster over the past five years (5.79% vs -9.17% CAGR).

Metrics side by side

Valuation

MetricBMRASNOA
P/S ratio1.470.26
P/B ratio2.490.88

Profitability

MetricBMRASNOA
Gross margin8.09%38.91%
Operating margin-119.54%-6.41%
Net margin-84.79%-10.33%
ROE-143.54%-34.33%
ROIC-117.93%-10.98%

Growth (annualized)

MetricBMRASNOA
Revenue CAGR (5Y)-9.17%5.79%
Total return CAGR (5Y)-46.66%-59.29%

Frequently asked

Which has grown faster, BMRA or SNOA?
Over the past five years, SNOA grew revenue faster — BMRA at a -9.17% CAGR versus SNOA at 5.79%.
How have BMRA and SNOA total returns compared?
Over the past 10 years, BMRA delivered -20.93% and SNOA delivered -47.31% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.